Cantharidin (Ycanth) (CPB 1051, reviewed 2025-12-23)
Summary
Cantharidin (Ycanth) is considered medically necessary for commercial medical plans for the topical treatment of molluscum contagiosum when all criteria are met: the member is 2 years of age or older, the member has a diagnosis of molluscum contagiosum, Ycanth is not used for oral, mucosal, or ophthalmic lesions, a healthcare professional who has received instruction and training administers it, and no more than 2 applicators are used in a single treatment session. Continuation of therapy is considered medically necessary for up to 4 treatment sessions (cycles) per infection when the same criteria are met. More than 4 treatment sessions and use for members under 2 years of age are considered experimental, investigational, or unproven, and all other indications are considered experimental, investigational, or unproven.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.